Multiple Myeloma Hub

Find out how ocular events associated with belantamab mafodotin in the DREAMM-7 and DREAMM-8 trials were effectively managed with dose modifications, including the impact on patient-reported outcomes. Learn more: loom.ly/Y6bYM8w #MultipleMyeloma #myeloma #MedNews #MedEd

New publication 📝 Results from the real-world REALiTEC study, published in @Haematologica, show teclistamab achieved an ORR of 60.2% (≥VGPR, 52.2%; ≥CR, 26.5%) in patients with relapsed/refractory #MultipleMyeloma. Learn more about RRMM: multiplemyelomahub.com/types/malignan… #myeloma #mmsm #MedNews #MedEd

In our latest podcast, Paul Richardson discusses the use of CELMoDs for the treatment of newly diagnosed and high-risk smoldering #MultipleMyeloma, including early clinical data and emerging treatment strategies. Listen here: bit.ly/4nj0ErO #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Check out our masterclass series on CELMoDs for the treatment of #MultipleMyeloma, featuring expert insights from Paul Richardson on mechanism of action, clinical data in relapsed/refractory disease, and emerging applications in earlier lines of therapy. Watch the full series here: bit.ly/4uTXI7q #myeloma #mmsm #MedEd

CELMoDs are now being evaluated in earlier lines of therapy, including newly diagnosed #MultipleMyeloma. Watch the full video here: bit.ly/4nj0ErO #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

New publication 📝 Real-world data from FREEDOMM, published in @AdvancesTherapy, show estimated 18-month TFI and OS rates of 80.3% and 93.4%, respectively, in patients with relapsed/refractory #MultipleMyeloma treated with cilta-cel after ≥4 prior LoT. Learn more: multiplemyelomahub.com/types/malignan… #myeloma #mmsm #MedNews #MedEd

New publication 📝 Real-world data, published in @BloodCancerJnl, show an ORR of 65% (≥CR, 36%) in patients with heavily pretreated (median 6 prior LoT) relapsed/refractory #MultipleMyeloma receiving elranatamab. Elevated LDH and low Hb were independently associated with poorer outcomes. Learn more: multiplemyelomahub.com/types/malignan… #myeloma #mmsm #MedNews #MedEd @AJPortuguese

CELMoDs represent a distinct class of novel oral agents targeting cereblon to drive selective protein degradation. Watch the full video featuring Paul Richardson here: bit.ly/4w64mJi #MultipleMyeloma #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

In our latest podcast, Paul Richardson discusses the mechanism of action of CELMoDs in #MultipleMyeloma, including immune activation and potential to overcome resistance to prior IMiD therapy. Listen here: shows.acast.com/mm-hub/episode…? #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

CELMoDs have demonstrated activity in patients with relapsed/refractory #MultipleMyeloma, including those with prior BCMA exposure. Watch the full video here: bit.ly/4tK5UHp #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

In our latest podcast, Paul Richardson discusses clinical data for CELMoDs in relapsed/refractory #MultipleMyeloma, including efficacy and safety in heavily pretreated patients and those with HRCA. Listen here: bit.ly/42wzFzq? #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

🔍 Looking for trusted, in-depth #MultipleMyeloma education? The Multiple Myeloma Hub's educational resource center has you covered. Browse a wealth of content all in one place. bit.ly/4cSCgIu   #mmsm #MedE

Learn more about the emerging role of CELMoDs in newly diagnosed and smoldering #MultipleMyeloma in our expert interview with Paul Richardson. Watch here: bit.ly/4nj0ErO #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

Listen to our latest podcast featuring a panel discussion chaired by Rakesh Popat on real-world experience with belantamab mafodotin in #MultipleMyeloma, including ocular toxicity management and patient perspectives. Listen here: bit.ly/4cniQwB #mmsm #myeloma #MedEd @DrRakeshPopat @HangQuach1 @MyelomaOslo Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence on our resources.

What clinical activity has been observed with CELMoDs in relapsed/refractory #MultipleMyeloma? Paul Richardson discusses response rates, safety, and emerging combination strategies. Watch here: bit.ly/4tK5UHp #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

New publication 📝 Real-world data, published in @BloodCancerJnl, show 97.4% hematologic recovery after SCB in patients with relapsed/refractory #MultipleMyeloma with CAR T-related cytopenias; Day 90 Hb and platelet counts were improved vs matched controls. Learn more: multiplemyelomahub.com/therapeutics/c… #myeloma #mmsm #MedNews #MedEd

Ocular adverse events with belantamab mafodotin are often predictable and manageable with dose-adjustment strategies. Watch the full video: bit.ly/4cniQwB #MultipleMyeloma #mmsm #myeloma #MedEd @DrRakeshPopat @HangQuach1 @MyelomaOslo Intended for healthcare professionals. Independently supported by GSK. Funders are allowed no influence on our resources.

Listen to our latest podcast featuring Hang Quach discussing dose modification strategies for BCMA-directed therapies in #MultipleMyeloma. Listen here: bit.ly/4mtxbLj #mmsm #myeloma #MedEd @HangQuach1 Intended for healthcare professionals only. This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

The Multiple Myeloma Hub spoke with Paul Richardson. We asked about CELMoDs for the treatment of relapsed/refractory #MultipleMyeloma. Watch here: bit.ly/4tK5UHp #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

How do CELMoDs differ from earlier immunomodulatory drugs? Paul Richardson discusses structural and functional differences and their clinical implications. Learn more here: bit.ly/4w64mJi #MultipleMyeloma #myeloma #mmsm #MedEd Intended for healthcare professionals only. This educational resource is independently supported by BMS. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.

New publication 📝 Real-world data, published in @JME_Journal, show outpatient vs inpatient cilta-cel administration reduced inpatient days in patients with R/R #MultipleMyeloma after ≥4 prior LoT (2.4 vs 6.6 days PPPM; aIRR, 0.37; p < 0.001), with similar TFI, OS, CRS, and ICANS between cohorts. Learn more: multiplemyelomahub.com/types/malignan… #myeloma #mmsm #MedNews #MedEd